Medicine and Dentistry
Neoplasm
100%
Pathologist
52%
Adenocarcinoma
48%
Immunohistochemistry
36%
Recurrent Disease
35%
Endometrium Carcinoma
33%
Lymph Node
33%
Metastatic Carcinoma
26%
Epidermal Growth Factor Receptor
22%
Colorectal Carcinoma
22%
Uterine Cancer
22%
Protein P53
20%
Disease
20%
Diagnosis
16%
Consultation
15%
Cohort Analysis
15%
Transgender
15%
Carcinoma
14%
Surgeon
12%
Sentinel Lymph Node Biopsy
12%
Adenomyosis
12%
Malignant Neoplasm
12%
Cancer Staging
12%
Cervicectomy
11%
Granulosa Cell Tumour
11%
Vulvar Cancer
11%
Pancreaticoduodenectomy
11%
Overall Survival
11%
Hysterectomy
11%
Lymph Node Metastasis
11%
Ovarian Tumor
10%
Lymphovascular Invasion
10%
Lymph Duct
10%
Small-Cell Carcinoma
10%
Chemotherapy
9%
P16
9%
Serous Carcinoma
9%
Surgery
9%
Cancer
9%
Krukenberg Tumor
9%
Morphology
9%
Cervical Cancer
9%
Wart Virus
8%
Biopsy Technique
8%
Pelvis Lymphadenectomy
7%
Vulva Carcinoma
7%
Androgen
7%
Cytotechnology
7%
Rectum Carcinoma
7%
Placenta
7%
Keyphrases
Tumor
48%
Pathologist
44%
Epidermal Growth Factor Receptor
22%
Carcinoma in Situ
21%
Endometrial Adenocarcinoma
20%
Intraoperative Consultation
19%
Metastasis
19%
Adenocarcinoma
18%
Endometrial Cancer
17%
Immunohistochemistry
16%
Endometrioid
16%
Lymphovascular Invasion
15%
Lymph Node
15%
Surgical Pathology
14%
Carcinoma
14%
Colorectal Cancer
13%
Human Epidermal Growth Factor Receptor 2 (HER2)
13%
Lymph Node Harvest
13%
Transgender
13%
Adenomyosis
12%
Sentinel Lymph Node Biopsy
12%
CDX2
12%
Immunostaining
12%
Overall Survival
11%
Surgeons
11%
Immunohistochemical Staining
11%
Population-based Cohort Study
11%
Pancreaticoduodenectomy
11%
Pathological Findings
11%
Hysterectomy
11%
Lymph Node Sampling
10%
Lymph Node Ratio
10%
Estrogen Receptor
10%
Small Cell Carcinoma
10%
Uterus
10%
Primary Tumor
10%
Pathology Report
9%
Resection Specimen
9%
Lymph Node Metastasis
9%
Intraoperative Assessment
9%
D2-40
9%
Serous Carcinoma
9%
Granular Cell Tumor
9%
Neoplasms
9%
High-risk Human Papillomavirus (HR-HPV)
9%
Endometrial Endometrioid Adenocarcinoma
8%
Vulvar Cancer
8%
Carcinoembryonic Antigen
8%
Ovarian Cancer
8%
Early-stage Cervical Cancer
8%